Navigation Links
New Anti Fungal Drug Eraxis as Good as the Older Medicine

Eraxis, known generically as anidulafungin was shown to be non-inferior to fluconazole in the treatment of invasive candidiasis, a potentially fatal blood infection seen in people whose immune systems have been hobbled. This is according to a research by Dr. Annette Reboli of Cooper University Hospital in Camden, New Jersey, and colleagues who published their findings in the New England Journal of Medicine.

But many other researchers believe that according to a new study the older, cheaper medication to treat potentially deadly fungal infections may work just as well as a newer drug in most cases.

Anidulafungin, belonging to a new class called echinocandins being expensive people would go for the fluconazole. And it was seen that it was the most prescribed.

Fungal infections may be a non-issue for most healthy people but they can be life-threatening for people who are already ill and for babies who are born pre-term and tiny.

The first compound used to treat candidiasis (yeast infection) was amphotericin B, which was effective but was limited by side effects. Over the years, less toxic alternatives were developed such as fluconazole and a newer class of drugs known as echinocandins, one of which is anidulafungin.

In the study conducted by Dr. Reboli, Eraxis, known generically as anidulafungin, cleared the fungal infections in nearly 76 percent of 127 volunteers, compared with 60 percent of the 118 patients given fluconazole. Side effects were the same in both the groups. The study was conducted to show that to show that Eraxis was not inferior to the generic treatment.

"I think we will see more use of echinocandins up front, especially in critically ill patients, and fluconazole or another one in that class when the patient has responded and turned a corner," said Dr.Reboli.

The results "are disappointing to those who sought a clear winner" between the two drugs, said Dr. Jack Sobel and Dr. Sanjay Revankar of Wayne State University School of Medicine in Detroit.

"There is absolutely no justification for abandoning fluconazole, given its safety, overall efficacy, and low cost. The price of echinocandins has dropped substantially but remains several fold higher than that of generic fluconazole," they wrote in a commentary, also published in the Journal.

A second study, conducted in Italy, found that giving fluconazole prophylactically to babies born preterm and weighing less than about 3 pounds at birth reduced the incidence of colonization and invasive Candida infection


Related medicine news :

1. Cure For Persistent Oral Fungal Problem May Be Possible
2. Fungal Infections Effectively Controlled By Light Therapy
3. Fungal spores in the pillows can trigger an asthma attack
4. Immunosuppressive Action Of Fungal Metabolite - Gliotoxin
5. Fungal toxins infected corn the reason for congenital defects
6. Contact Lenses Implicated in Fungal Infections
7. Spread Of Fungal Infections At Gym Could Be Avoided By Using Towel
8. Lens Wearers Alerted Over Dangerous Fungal Infection
9. Reports Characterize Fungal Eye Infections Among Soft Contact Lens Wearers
10. Noxafil Can Help Invasive Fungal Infections
11. Noxafil Drug Better in Fighting Deadly Fungal Infections
Post Your Comments:

(Date:12/1/2015)... ... December 01, 2015 , ... ... continuing medical education (CME), today announced that the first annual School of Gastrointestinal ... , “The prevention, detection and treatment of gastrointestinal cancers are undergoing transformational change, ...
(Date:12/1/2015)... ... 01, 2015 , ... Speech and physical therapies are traditionally ... technologies and under the right circumstances, these practices can be merged. This ... to his or her therapeutic sessions, as well as gives the physical and ...
(Date:12/1/2015)... ... December 01, 2015 , ... CloudLIMS ... 2015 Golden Bridge Business Awards under the New Products and Services category for ... based sample management software that helps labs organize data and track ...
(Date:12/1/2015)... CHICAGO (PRWEB) , ... December 01, 2015 , ... ... risk quantification and optimization of adjunctive imaging is the focus of numerous abstracts ... (RSNA) meeting, November 29-December 4, 2015. Nine abstracts highlight the use of ...
(Date:12/1/2015)... ... 01, 2015 , ... SAN FRANCISCO, Calif. (December 1, 2015) ... has awarded Education and Developmental Therapies (EDT), an Applied Behavior Analysis (ABA) service ... special needs providers that excel in synthesizing the areas of clinical quality, staff ...
Breaking Medicine News(10 mins):
(Date:12/1/2015)... SAN FRANCISCO , Dec. 1, 2015  InCarda ... the development and commercialization of therapies for cardiovascular conditions ... established a subsidiary business in Australia ... clinical trial in Australia in ... with leading investigators and medical centers in ...
(Date:12/1/2015)... SALT LAKE CITY , Dec. 1, 2015  Booth ... at booth #3506 during the annual meeting of the Radiological ... Chicago this year. Based in ... Imaging Components business of Varian Medical Systems (NYSE: VAR ... high voltage connectors, ionization chambers and solid state automatic exposure ...
(Date:12/1/2015)... -- Olea Sensor Networks, a leader in intelligent sensors and analytic software for sensor network-based systems, ... real-time data collection of vital signs. Photo ... ... ... ...
Breaking Medicine Technology: